Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

173.29USD
17 Feb 2017
Change (% chg)

$1.18 (+0.69%)
Prev Close
$172.11
Open
$171.35
Day's High
$173.36
Day's Low
$168.89
Volume
4,154,875
Avg. Vol
3,952,400
52-wk High
$176.85
52-wk Low
$133.64

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $127,619.90
Shares Outstanding(Mil.): 736.45
Dividend: 1.15
Yield (%): 2.65

Financials

  AMGN.O Industry Sector
P/E (TTM): 16.89 47.80 29.39
EPS (TTM): 10.26 -- --
ROI: 11.95 -4.08 13.06
ROE: 26.65 4.84 14.19

BRIEF-Amgen Inc files for potential mixed shelf size not disclosed

* Amgen Inc - files for potential mixed shelf; size not disclosed Source text:(http://bit.ly/2lhl0EQ) Further company coverage:

Feb 14 2017

BRIEF-Regeneron says price increases unrelated from innovation will be pushed back on

* Regeneron CEO: "As we further diversify our product related revenue stream, we do not plan to provide eylea guidance after 2017"

Feb 09 2017

UPDATE 2-Regeneron, Sanofi win stay of U.S. order blocking cholesterol drug sales

Feb 8 A U.S. appeals court on Wednesday stayed an order that would have blocked Regeneron Pharmaceuticals Inc and Sanofi SA from selling their cholesterol drug, Praluent, while they appeal the order.

Feb 08 2017

Regeneron, Sanofi win stay of order blocking cholesterol drug sales

Feb 8 A U.S. appeals court on Wednesday has stayed an order that would have blocked Regeneron Pharmaceuticals Inc and Sanofi SA from selling their cholesterol drug, Praluent, later this month while they appeal.

Feb 08 2017

FDA approves Amgen drug for secondary hyperparathyroidism

The U.S. Food and Drug Administration has approved Amgen Inc's treatment for secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis, the U.S. biotech company said on Tuesday.

Feb 07 2017

BRIEF-FDA approves Amgen's Parsabiv, first new treatment in more than a decade for secondary hyperparathyroidism in adult patients on hemodialysis

* FDA approves Amgen's Parsabiv (etelcalcetide), first new treatment in more than a decade for secondary hyperparathyroidism in adult patients on hemodialysis

Feb 07 2017

U.S. FDA approves Amgen drug for secondary hyperparathyroidism

Feb 7 The U.S. Food and Drug Administration has approved Amgen Inc's treatment for secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis, the U.S. biotech company said on Tuesday.

Feb 07 2017

BRIEF-Amgen appoints Charles Holley Jr. to board of directors

* Amgen announces appointment of Charles M. Holley Jr. To board of directors

Feb 03 2017

Wall Street stalls as market, Trump priorities diverge

NEW YORK U.S. stocks ended little changed on Thursday as the recent rally continued to stall following President Donald Trump's latest comments on trade and the policies he will pursue. | Video

Feb 02 2017

BRIEF-Amgen CEO expects to see U.S. tax reform

* Amgen CEO says international expansion important element of long-term growth

Feb 02 2017

More From Around the Web

Earnings vs. Estimates